https://m2.mtmt.hu/ hun 2026-10-23 17:45 JournalArticle 37057169 VALIDATED true 0 false 2026-09-02T11:00:01.115+0000 2026-05-20T08:50:10.732+0000 2026-04-01T12:27:12.254+0000 true 10101476 Balázs Katalin /api/admin/10101476 Admin Balázs Katalin (admin) false 2026-05-22T21:28:04.855+0000 2026-05-20T08:50:10.668+0000 true 521 Szuper Admin /api/admin/521 Admin Szuper Admin (admin) true true true true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Antal-Szalmás, Péter true true /api/journal/20070331 REVIEWED JOURNAL OF TRANSLATIONAL AUTOIMMUNITY 2589-9090 true false false 20070331 true 2589-9090 Journal FOREIGN 12 100366 100366 2026 true 2026 true true true false true false GOLD 2026-09-02 false https://www.sciencedirect.com/journal/journal-of-translational-autoimmunity 2 0 2 2 0 2 2 2 2 2 2 2 2 2 0 0 2 2 2 2 0 2 2 Folyóiratcikk Journal Article 24 2 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2026 0 2 2 2 2 Q2 false false false false 2026-06-30T12:33:38.737+0000 Gasztroenterológiai Tanszék (DE / ÁOK / BelgyI); Immunológiai Intézet (DE / ÁOK); Klinikai Laboratóriumi Kutató Tanszék (DE / ÁOK / LMI); Laboratóriumi Medicina Intézet (DE / ÁOK) 6 24 4 9 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 136713373 /api/authorship/136713373 Antal-Szalmás, Péter [Antal-Szalmás, Péter (Immunológia), szerző] Laboratóriumi Medicina Intézet (DE / ÁOK) 1 0.111 true false false Author 10009455 /api/author/10009455 Antal-Szalmás Péter (Immunológia) Antal-Szalmás Péter true 10009455 true Antal-Szalmás Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 136713374 /api/authorship/136713374 Bencze, Dóra [Bencze, Dóra (immunológia, labo...), szerző] Immunológiai Intézet (DE / ÁOK) 2 0.111 false false false Author 10068399 /api/author/10068399 Bencze Dóra (immunológia, laboratóriumi medicina) Bencze Dóra true true Bencze Dóra true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 136713375 /api/authorship/136713375 Demeter, Sarolta 3 0.11111111 false false false Demeter Sarolta true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 136713376 /api/authorship/136713376 Pénzes-Daku, Krisztina [Pénzes-Daku, Krisztina (trombózis-hemoszt...), szerző] Klinikai Laboratóriumi Kutató Tanszék (DE / ÁOK / LMI) 4 0.111 false false false Author 10036832 /api/author/10036832 Pénzes-Daku Krisztina (trombózis-hemosztázis) Pénzes-Daku Krisztina true 10036832 true Pénzes-Daku Krisztina true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 136713377 /api/authorship/136713377 Szabó, Lilla 5 0.11111111 false false false Szabó Lilla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 136713378 /api/authorship/136713378 Tóth, Beáta [Tóth, Beáta (molekuláris biológia), szerző] Laboratóriumi Medicina Intézet (DE / ÁOK) 6 0.111 false false false Author 10036104 /api/author/10036104 Tóth Beáta (molekuláris biológia) Tóth Beáta true 10036104 true Tóth Beáta true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 136713379 /api/authorship/136713379 Földesi, Róza 7 0.11111111 false false false Földesi Róza true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 136713380 /api/authorship/136713380 Papp, Mária [Papp, Mária (Belgyógyászat, ga...), szerző] Gasztroenterológiai Tanszék (DE / ÁOK / BelgyI) 8 0.111 false false false Author 10015739 /api/author/10015739 Papp Mária (Belgyógyászat, gasztroenterológia) Papp Mária true 10015739 true Papp Mária true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 136713381 /api/authorship/136713381 Nagy, Gábor [Nagy, Gábor (laboratóriumi dia...), szerző] Laboratóriumi Medicina Intézet (DE / ÁOK) 9 0.111 false true false Author 10078258 /api/author/10078258 Nagy Gábor (laboratóriumi diagnosztika) Nagy Gábor true true Nagy Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 31781826 /api/publicationidentifier/31781826 DOI: 10.1016/j.jtauto.2026.100366 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1016/j.jtauto.2026.100366 https://doi.org/10.1016/j.jtauto.2026.100366 false true PublicationIdentifier 31891029 /api/publicationidentifier/31891029 WoS: 001734367500001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001734367500001 https://www.webofscience.com/wos/woscc/full-record/001734367500001 false true PublicationIdentifier 31891030 /api/publicationidentifier/31891030 Scopus: 105034685687 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105034685687 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105034685687 false true PublicationIdentifier 31781827 /api/publicationidentifier/31781827 Egyéb URL: https://linkinghub.elsevier.com/retrieve/pii/S2589909026000195 PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true https://linkinghub.elsevier.com/retrieve/pii/S2589909026000195 https://linkinghub.elsevier.com/retrieve/pii/S2589909026000195 false true SjrRating 11695555 /api/sjrrating/11695555 sjr:Q2 (2026) Scopus - Immunology Journal of Translational Autoimmunity 2589-9090 2589-9090 84 0.49 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2403 /api/classificationexternal/2403 Scopus - Immunology true 2403 true Q2 FROM_LAST_YEAR true true Reference 74181682 /api/reference/74181682 1. Beuers 2015: Changing nomenclature for PBC: from ‘Cirrhosis’ to ‘Cholangitis’., Am. J. Gastroenterol., 110, p. 1536, DOI: 10.1038/ajg.2015.312 1 10.1038/ajg.2015.312 false true Reference 74181683 /api/reference/74181683 2. Metcalf 1996: Natural history of early primary biliary cirrhosis., Lancet, 348, p. 1399, DOI: 10.1016/S0140-6736(96)04410-8 2 10.1016/S0140-6736(96)04410-8 false true Reference 74181684 /api/reference/74181684 3. Imam 2014: The natural history of primary biliary cirrhosis., Semin. Liver Dis., 34, p. 329, DOI: 10.1055/s-0034-1383731 3 10.1055/s-0034-1383731 false true Reference 74181685 /api/reference/74181685 4. Lindor 2009: American association for study of liver diseases, primary biliary cirrhosis., Hepatology, 50, p. 291, DOI: 10.1002/hep.22906 4 10.1002/hep.22906 false true Reference 74181686 /api/reference/74181686 5. Yehezkel 2021: Real-world management of patients with primary biliary Cholangitis-A retrospective study from a tertiary medical center in Israel., J. Clin. Med., 10, p. 4551, DOI: 10.3390/jcm10194551 5 10.3390/jcm10194551 false true Reference 74181687 /api/reference/74181687 6. You 2022: APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis., Hepatol. Int., 16, p. 1, DOI: 10.1007/s12072-021-10276-6 6 10.1007/s12072-021-10276-6 false true Reference 74181688 /api/reference/74181688 7. Lv 2021: Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta‐analysis., J. Gastroenterol. Hepatol., 36, p. 1423, DOI: 10.1111/jgh.15329 7 10.1111/jgh.15329 false true Reference 74181689 /api/reference/74181689 8. Rigopoulou 2023: Role of autoantibodies in the clinical management of primary biliary cholangitis., World J. Gastroenterol., 29, p. 1795, DOI: 10.3748/wjg.v29.i12.1795 8 10.3748/wjg.v29.i12.1795 false true Reference 74181690 /api/reference/74181690 9. Lleo 2020: Primary biliary cholangitis., Lancet Lond. Engl., 396, p. 1915, DOI: 10.1016/S0140-6736(20)31607-X 9 10.1016/S0140-6736(20)31607-X false true Reference 74181691 /api/reference/74181691 10. 2017: EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis., J. Hepatol., 67, p. 145, DOI: 10.1016/j.jhep.2017.03.022 10 10.1016/j.jhep.2017.03.022 false true Reference 74181692 /api/reference/74181692 11. Boonstra 2014: The Epi PSC PBC study group, rising incidence and prevalence of primary biliary cirrhosis: a large population‐based study., Liver Int., 34, DOI: 10.1111/liv.12434 11 10.1111/liv.12434 false true Reference 74181693 /api/reference/74181693 12. Griffiths 2014: The new epidemiology of primary biliary cirrhosis., Semin. Liver Dis., 34, p. 318, DOI: 10.1055/s-0034-1383730 12 10.1055/s-0034-1383730 false true Reference 74181694 /api/reference/74181694 13. Efe 2021: Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence and significance for clinical presentation and disease outcome., J. Gastroenterol. Hepatol., 36, p. 936, DOI: 10.1111/jgh.15214 13 10.1111/jgh.15214 false true Reference 74181695 /api/reference/74181695 14. Chalifoux 2017: Extrahepatic manifestations of primary biliary cholangitis., Gut Liver, 11, p. 771, DOI: 10.5009/gnl16365 14 10.5009/gnl16365 false true Reference 74181696 /api/reference/74181696 15. Leung 1997: Antimitochondrial antibodies in primary biliary cirrhosis., Semin. Liver Dis., 17, p. 61, DOI: 10.1055/s-2007-1007183 15 10.1055/s-2007-1007183 false true Reference 74181697 /api/reference/74181697 16. Hu 2014: Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis., PLoS One, 9 16 false true Reference 74181698 /api/reference/74181698 17. Muratori 2002: Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders., Clin. Exp. Immunol., 127, p. 172, DOI: 10.1046/j.1365-2249.2002.01719.x 17 10.1046/j.1365-2249.2002.01719.x false true Reference 74181699 /api/reference/74181699 18. Bauer 2013: Detection of anti-SP100 antibodies in primary biliary cirrhosis. Comparison of ELISA and immunofluorescence., J. Immunoassay Immunochem., 34, p. 346, DOI: 10.1080/15321819.2012.741088 18 10.1080/15321819.2012.741088 false true Reference 74181700 /api/reference/74181700 19. Itoh 1998: Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis., J. Gastroenterol. Hepatol., 13, p. 257, DOI: 10.1111/j.1440-1746.1998.01553.x 19 10.1111/j.1440-1746.1998.01553.x false true Reference 74181701 /api/reference/74181701 20. Bogdanos 2007: Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis., Hepatology, 45, p. 1583, DOI: 10.1002/hep.21678 20 10.1002/hep.21678 false true Reference 74181702 /api/reference/74181702 21. Rigamonti 2006: Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis., Gut, 55, p. 388, DOI: 10.1136/gut.2005.075002 21 10.1136/gut.2005.075002 false true Reference 74181703 /api/reference/74181703 22. Nakamura 2007: Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis., Hepatology, 45, p. 118, DOI: 10.1002/hep.21472 22 10.1002/hep.21472 false true Reference 74181704 /api/reference/74181704 23. Reig 2020: Novel anti-hexokinase 1 antibodies are associated with poor prognosis in patients with primary biliary cholangitis., Am. J. Gastroenterol., 115, p. 1634, DOI: 10.14309/ajg.0000000000000690 23 10.14309/ajg.0000000000000690 false true Reference 74181705 /api/reference/74181705 24. Norman 2015: Anti‐kelch‐like 12 and anti‐hexokinase 1: novel autoantibodies in primary biliary cirrhosis., Liver Int., 35, p. 642, DOI: 10.1111/liv.12690 24 10.1111/liv.12690 false true Reference 74181706 /api/reference/74181706 25. Nguyen 2022: A review on biomarkers for the evaluation of autoimmune cholestatic liver diseases and their overlap syndromes., Front. Mol. Med., 2, DOI: 10.3389/fmmed.2022.914505 25 10.3389/fmmed.2022.914505 false true Reference 74181707 /api/reference/74181707 26. Hu 2013: Clinical significance and prevalence of anti-Saccharomyces cerevisiae antibody in Chinese patients with primary biliary cirrhosis., Clin. Exp. Med., 13, p. 245, DOI: 10.1007/s10238-012-0207-4 26 10.1007/s10238-012-0207-4 false true Reference 74181708 /api/reference/74181708 27. Rigopoulou 2008: Molecular diagnostics of primary biliary cirrhosis., Expert Opin. Med. Diagn., 2, p. 621, DOI: 10.1517/17530059.2.6.621 27 10.1517/17530059.2.6.621 false true Reference 74181709 /api/reference/74181709 28. Granito 2007: Antibodies to SS‐A/Ro‐52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis., Aliment. Pharmacol. Ther., 26, p. 831, DOI: 10.1111/j.1365-2036.2007.03433.x 28 10.1111/j.1365-2036.2007.03433.x false true Reference 74181710 /api/reference/74181710 29. Van Beers 2022: The role of autoantibodies in the diagnosis of autoimmune liver disease: lessons learned from clinical practice., J. Appl. Lab. Med., 7, p. 259, DOI: 10.1093/jalm/jfab099 29 10.1093/jalm/jfab099 false true Reference 74181711 /api/reference/74181711 30. Lindor 2019: Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases., Hepatology, 69, p. 394, DOI: 10.1002/hep.30145 30 10.1002/hep.30145 false true Reference 74181712 /api/reference/74181712 31. Hirschfield 2018: The British society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines., Gut, 67, p. 1568, DOI: 10.1136/gutjnl-2017-315259 31 10.1136/gutjnl-2017-315259 false true Reference 74181713 /api/reference/74181713 32. Yang 2024: Diagnostic value of anti-hexokinase 1 and anti-kelch-like 12 antibodies in primary biliary cholangitis patients., J. Lab. Med., 48, p. 129, DOI: 10.1515/labmed-2023-0127 32 10.1515/labmed-2023-0127 false true Reference 74181714 /api/reference/74181714 33. Leung 2007: Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis., Hepatol. Baltim. Md, 46, p. 1436, DOI: 10.1002/hep.21828 33 10.1002/hep.21828 false true Reference 74181715 /api/reference/74181715 34. Pope 1999: Antimitochondrial antibodies and their significance in diffuse and limited scleroderma., J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis., 5, p. 206 34 false true Reference 74181716 /api/reference/74181716 35. Pelka 2021: Prevalence of antimitochondrial antibodies in subacute cutaneous lupus erythematosus., Int. J. Dermatol., 60, p. 88, DOI: 10.1111/ijd.15225 35 10.1111/ijd.15225 false true Reference 74181717 /api/reference/74181717 36. Duan 2022: The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC., Hepatol. Commun., 6, p. 3112, DOI: 10.1002/hep4.2067 36 10.1002/hep4.2067 false true Reference 74181718 /api/reference/74181718 37. Manuel Lucena 2007: Comparison of two ELISA assays for anti-Sp100 determination., Ann. N. Y. Acad. Sci., 1109, p. 203, DOI: 10.1196/annals.1398.024 37 10.1196/annals.1398.024 false true Reference 74181719 /api/reference/74181719 38. Papamichalis 2021: Promyelocytic leukemia antigen expression: a histological marker for primary biliary cholangitis diagnosis?., J. Transl. Intern. Med., 9, p. 43, DOI: 10.2478/jtim-2021-0008 38 10.2478/jtim-2021-0008 false true Reference 74181720 /api/reference/74181720 39. Wichmann 2003: Clinical significance of anti-multiple nuclear dots/Sp100 autoantibodies., Scand. J. Gastroenterol., 38, p. 996, DOI: 10.1080/00365520310004876 39 10.1080/00365520310004876 false true Reference 74181721 /api/reference/74181721 40. Gulati 2010: Primary Sjogren's syndrome with anticentromere antibodies--a clinically distinct subset., Clin. Rheumatol., 29, p. 789, DOI: 10.1007/s10067-009-1359-9 40 10.1007/s10067-009-1359-9 false true Reference 74181722 /api/reference/74181722 41. Florin 2020: Evaluation of the primary biliary cholangitis-related serologic profile in a large cohort of Belgian systemic sclerosis patients., Clin. Chem. Lab. Med., 58, p. 416, DOI: 10.1515/cclm-2019-0655 41 10.1515/cclm-2019-0655 false true Reference 74181723 /api/reference/74181723 42. Lepri 2023: Systemic sclerosis and primary biliary cholangitis: longitudinal data to determine the outcomes., J. Scleroderma Relat. Disord., 8, p. 210, DOI: 10.1177/23971983231155948 42 10.1177/23971983231155948 false true Reference 74181724 /api/reference/74181724 43. Uchida 2005: Identification of specific autoantigens in Sjögren’s syndrome by SEREX., Immunology, 116, p. 53, DOI: 10.1111/j.1365-2567.2005.02197.x 43 10.1111/j.1365-2567.2005.02197.x false true Reference 74181725 /api/reference/74181725 44. Burbelo 2022: Autoantibodies against proteins previously associated with autoimmunity in adult and pediatric patients with COVID-19 and children with MIS-C., Front. Immunol., 13, DOI: 10.3389/fimmu.2022.841126 44 10.3389/fimmu.2022.841126 false true Reference 74181726 /api/reference/74181726 45. Chang 2022: Anti-mitochondrial antibody titers decrease over time in primary biliary cholangitis patients with ursodeoxycholic acid therapeutic response: a cohort study followed up to 28 years., Front. Immunol., 13, DOI: 10.3389/fimmu.2022.869018 45 10.3389/fimmu.2022.869018 false true Reference 74181727 /api/reference/74181727 46. Heseltine 1990: Primary biliary cirrhosis., Gastroenterology, 99, p. 1786, DOI: 10.1016/0016-5085(90)90488-M 46 10.1016/0016-5085(90)90488-M false true Reference 74181728 /api/reference/74181728 47. Christensen 1980: Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients., Gastroenterology, 78, p. 236, DOI: 10.1016/0016-5085(80)90571-5 47 10.1016/0016-5085(80)90571-5 false true Reference 74181729 /api/reference/74181729 48. Gao 2008: The value of antinuclear antibodies in primary biliary cirrhosis., Clin. Exp. Med., 8, p. 9, DOI: 10.1007/s10238-008-0150-6 48 10.1007/s10238-008-0150-6 false true Reference 74181730 /api/reference/74181730 49. Ding 2025: The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: enhancing the prognostic utility on the GLOBE scoring system., Dig. Liver Dis., 57, p. 861, DOI: 10.1016/j.dld.2024.12.024 49 10.1016/j.dld.2024.12.024 false true Reference 74181731 /api/reference/74181731 50. Liberal 2013: Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis., Clin. Res. Hepatol. Gastroenterol., 37, p. 572, DOI: 10.1016/j.clinre.2013.04.005 50 10.1016/j.clinre.2013.04.005 false true Reference 74181732 /api/reference/74181732 51. Ma 2024: Dissecting causal relationships between primary biliary cholangitis and extrahepatic autoimmune diseases based on Mendelian randomization., Sci. Rep., 14 51 false true Reference 74181733 /api/reference/74181733 52. Mandai 2013: Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis., Clin. Exp. Nephrol., 17, p. 405, DOI: 10.1007/s10157-012-0724-1 52 10.1007/s10157-012-0724-1 false true Reference 74181734 /api/reference/74181734 53. Shi 2013: Risk factors for hepatic decompensation in patients with primary biliary cirrhosis., World J. Gastroenterol., 19, p. 1111, DOI: 10.3748/wjg.v19.i7.1111 53 10.3748/wjg.v19.i7.1111 false true Reference 74181735 /api/reference/74181735 54. Yang 2004: Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?., Clin. Gastroenterol. Hepatol., 2, p. 1116, DOI: 10.1016/S1542-3565(04)00465-3 54 10.1016/S1542-3565(04)00465-3 false true Reference 74181736 /api/reference/74181736 55. Haldar 2021: Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis., Liver Int. Off. J. Int. Assoc. Study Liver, 41, p. 535 55 false true Reference 74181737 /api/reference/74181737 56. Nakamura 2015: Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis., Hepatol. Res. Off. J. Jpn. Soc. Hepatol., 45, p. 846, DOI: 10.1111/hepr.12423 56 10.1111/hepr.12423 false true Reference 74181738 /api/reference/74181738 57. Qian 2020: Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators., Clin. Res. Hepatol. Gastroenterol., 44, p. 874, DOI: 10.1016/j.clinre.2020.03.026 57 10.1016/j.clinre.2020.03.026 false true Reference 74181739 /api/reference/74181739 58. Chen 2022: The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China., Dig. Liver Dis., 54, p. 1094, DOI: 10.1016/j.dld.2021.10.011 58 10.1016/j.dld.2021.10.011 false true Reference 74181740 /api/reference/74181740 59. Yang 2017: The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210., Aliment. Pharmacol. Ther., 45, p. 733, DOI: 10.1111/apt.13927 59 10.1111/apt.13927 false true Reference 74181741 /api/reference/74181741 60. Huang 2019: Early prognostic utility of Gp210 antibody-positive rate in primary biliary cholangitis: a meta-analysis., Dis. Markers, 2019, DOI: 10.1155/2019/9121207 60 10.1155/2019/9121207 false true Reference 74181742 /api/reference/74181742 61. Invernizzi 2005: Antinuclear antibodies in primary biliary cirrhosis., Semin. Liver Dis., 25, p. 298, DOI: 10.1055/s-2005-916321 61 10.1055/s-2005-916321 false true Reference 74181743 /api/reference/74181743 62. Wang 2024: Autoantibodes to GP210 are a metric for UDCA responses in primary biliary cholangitis., J. Transl. Autoimmun., 8, DOI: 10.1016/j.jtauto.2024.100239 62 10.1016/j.jtauto.2024.100239 false true Reference 74181744 /api/reference/74181744 63. Bauer 2022: Diagnostic and clinical value of specific autoantibodies against kelch-like 12 peptide and nuclear envelope proteins in patients with primary biliary cholangitis., Biomedicines, 10, p. 801, DOI: 10.3390/biomedicines10040801 63 10.3390/biomedicines10040801 false true Reference 74181745 /api/reference/74181745 64. Tana 2015: The significance of autoantibody changes over time in primary biliary cirrhosis., Am. J. Clin. Pathol., 144, p. 601, DOI: 10.1309/AJCPQV4A7QAEEFEV 64 10.1309/AJCPQV4A7QAEEFEV false true Reference 74181746 /api/reference/74181746 65. Sturrock 2018: PBC specific ANAs and UDCA response., J. Gastroenterol. Hepatol. Res., 7, p. 2741 65 false true Reference 74181747 /api/reference/74181747 66. Bauer 2021: Analysis of autoantibodies against promyelocytic leukemia nuclear body components and biochemical parameters in sera of patients with primary biliary cholangitis., Diagnostics, 11, p. 587, DOI: 10.3390/diagnostics11040587 66 10.3390/diagnostics11040587 false true Reference 74181748 /api/reference/74181748 67. Züchner 1997: Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis., Hepatology, 26, p. 1123 67 false true Reference 74181749 /api/reference/74181749 68. Lindor 2022: Primary biliary cholangitis: 2021 practice guidance update from the American association for the study of liver diseases., Hepatology, 75, p. 1012, DOI: 10.1002/hep.32117 68 10.1002/hep.32117 false true Reference 74181750 /api/reference/74181750 69. Alfano 2017: Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: is it possible to predict the course of the disease?., Immunol. Res., 65, p. 299, DOI: 10.1007/s12026-016-8838-2 69 10.1007/s12026-016-8838-2 false true Reference 74181751 /api/reference/74181751 70. Gabeta 2007: Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis., J. Clin. Immunol., 27, p. 378, DOI: 10.1007/s10875-007-9092-0 70 10.1007/s10875-007-9092-0 false true Reference 74181752 /api/reference/74181752 71. Gatselis 2013: Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease., Autoimmunity, 46, p. 471, DOI: 10.3109/08916934.2013.801461 71 10.3109/08916934.2013.801461 false true Reference 74181753 /api/reference/74181753 72. Wang 2024: Clinical performance of AMA‐M2, anti‐gp210 and anti‐sp100 antibody levels in primary biliary cholangitis: when detected by multiplex bead‐based flow fluorescent immunoassay., Immun. Inflamm. Dis., 12, DOI: 10.1002/iid3.1161 72 10.1002/iid3.1161 false true Reference 74181754 /api/reference/74181754 73. Dellavance 2013: Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis., Hepatol. Int., 7, p. 775, DOI: 10.1007/s12072-012-9413-0 73 10.1007/s12072-012-9413-0 false true Reference 74181755 /api/reference/74181755 74. Murillo Perez 2022: Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls., Gastroenterology, 163, p. 1630, DOI: 10.1053/j.gastro.2022.08.054 74 10.1053/j.gastro.2022.08.054 false true Reference 74181756 /api/reference/74181756 75. Nakamura 2005: Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis., J. Hepatol., 42, p. 386, DOI: 10.1016/j.jhep.2004.11.016 75 10.1016/j.jhep.2004.11.016 false true Reference 74181757 /api/reference/74181757 76. Nakamura 2006: Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis., J. Autoimmun., 26, p. 138, DOI: 10.1016/j.jaut.2005.10.007 76 10.1016/j.jaut.2005.10.007 false true Reference 74181758 /api/reference/74181758 77. Mytilinaiou 2012: Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis., Clin. Chim. Acta Int. J. Clin. Chem., 413, p. 1211, DOI: 10.1016/j.cca.2012.03.020 77 10.1016/j.cca.2012.03.020 false true Reference 74181759 /api/reference/74181759 78. Parveen 1995: High prevalence of antibodies to recombinant CENP‐B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities., J. Gastroenterol. Hepatol., 10, p. 438, DOI: 10.1111/j.1440-1746.1995.tb01597.x 78 10.1111/j.1440-1746.1995.tb01597.x false true Reference 74181760 /api/reference/74181760 79. Bin 2020: Detection of anti-kelch-like 12 and anti-hexokinase 1 antibodies in primary biliary cholangitis patients in China., Rev. Esp. Enferm. Dig., DOI: 10.17235/reed.2020.7483/2020 79 10.17235/reed.2020.7483/2020 false true Reference 74181761 /api/reference/74181761 80. Lleo 2012: Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis., Hepatology, 55, p. 153, DOI: 10.1002/hep.24630 80 10.1002/hep.24630 false true Reference 74181762 /api/reference/74181762 81. Poupon 1999: Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis., J. Hepatol., 30, p. 408, DOI: 10.1016/S0168-8278(99)80098-1 81 10.1016/S0168-8278(99)80098-1 false true Reference 74181763 /api/reference/74181763 82. Corpechot 2004: Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA‐treated patients with primary biliary cirrhosis., Liver Int., 24, p. 187, DOI: 10.1111/j.1478-3231.2004.0918.x 82 10.1111/j.1478-3231.2004.0918.x false true Reference 74181764 /api/reference/74181764 83. Kuiper 2009: Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid., Gastroenterology, 136, p. 1281, DOI: 10.1053/j.gastro.2009.01.003 83 10.1053/j.gastro.2009.01.003 false true Reference 74181765 /api/reference/74181765 84. Zhang 2013: Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study., Hepatology, 58, p. 264, DOI: 10.1002/hep.26322 84 10.1002/hep.26322 false true Reference 74181766 /api/reference/74181766 85. Lammers 2015: Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy., Gastroenterology, 149, p. 1804, DOI: 10.1053/j.gastro.2015.07.061 85 10.1053/j.gastro.2015.07.061 false true Reference 74181767 /api/reference/74181767 86. Carbone 2016: The UK‐PBC risk scores: derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis., Hepatology, 63, p. 930, DOI: 10.1002/hep.28017 86 10.1002/hep.28017 false true Reference 74181768 /api/reference/74181768 87. Chen 2017: A brief review on prognostic models of primary biliary cholangitis., Hepatol. Int., 11, p. 412, DOI: 10.1007/s12072-017-9819-9 87 10.1007/s12072-017-9819-9 false true Reference 74181769 /api/reference/74181769 88. Efe 2019: Validation of risk scoring systems in ursodeoxycholic acid–treated patients with primary biliary cholangitis., Am. J. Gastroenterol., 114, p. 1101, DOI: 10.14309/ajg.0000000000000290 88 10.14309/ajg.0000000000000290 false true Reference 74181770 /api/reference/74181770 89. Jallouli 2025: Primary biliary cholangitis: a summary of pathogenesis and therapies., Ann. Gastroenterol., DOI: 10.20524/aog.2025.0953 89 10.20524/aog.2025.0953 false true Reference 74181771 /api/reference/74181771 90. Mijic 2022: Pretransplant evaluation and liver transplantation outcome in PBC patients., Chin. J. Gastroenterol. Hepatol., 2022 90 false true Reference 74181772 /api/reference/74181772 91. Poupon 1991: The UDCA–PBC study group∗, A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis., N. Engl. J. Med., 324, p. 1548, DOI: 10.1056/NEJM199105303242204 91 10.1056/NEJM199105303242204 false true Reference 74181773 /api/reference/74181773 92. Tang 2017: Evidence for the association between IgG‐antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis., J. Gastroenterol. Hepatol., 32, p. 659, DOI: 10.1111/jgh.13534 92 10.1111/jgh.13534 false true Reference 74181774 /api/reference/74181774 93. Kisand 1996: Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis., J. Mol. Med., 74, p. 269, DOI: 10.1007/BF00196579 93 10.1007/BF00196579 false true Reference 74181775 /api/reference/74181775 94. Hazama 2000: Serial changes in enzyme inhibitory antibody to pyruvate dehydrogenase complex during the course of primary biliary cirrhosis., J. Clin. Lab. Anal., 14, p. 208, DOI: 10.1002/1098-2825(2000)14:5&lt;208::AID-JCLA2&gt;3.0.CO;2-6 94 10.1002/1098-2825(2000)14:5&lt;208::AID-JCLA2&gt;3.0.CO;2-6 false true Reference 74181776 /api/reference/74181776 95. Benson 2004: Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis., J. Immunol. Res., 11, p. 129, DOI: 10.1080/10446670410001722113 95 10.1080/10446670410001722113 false true Reference 74181777 /api/reference/74181777 96. Kikuchi 2009: Ursodeoxycholic acid reduces CpG‐induced IgM production in patients with primary biliary cirrhosis., Hepatol. Res., 39, p. 448, DOI: 10.1111/j.1872-034X.2008.00474.x 96 10.1111/j.1872-034X.2008.00474.x false true Reference 74181778 /api/reference/74181778 97. Feng 2020: Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: a single center study from China., PLoS One, 15, DOI: 10.1371/journal.pone.0242164 97 10.1371/journal.pone.0242164 false true Reference 74181779 /api/reference/74181779 98. Van Norstrand 1997: Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression., Hepatology, 25, p. 6, DOI: 10.1002/hep.510250103 98 10.1002/hep.510250103 false true Reference 74181780 /api/reference/74181780 99. Yin 2012: B cell depletion in treating primary biliary cirrhosis: pros and cons., World J. Gastroenterol., 18, p. 3938, DOI: 10.3748/wjg.v18.i30.3938 99 10.3748/wjg.v18.i30.3938 false true Reference 74181781 /api/reference/74181781 100. Dohmen 2004: Fenofibrate for patients with asymptomatic primary biliary cirrhosis., World J. Gastroenterol., 10, p. 894, DOI: 10.3748/wjg.v10.i6.894 100 10.3748/wjg.v10.i6.894 false true Reference 74181782 /api/reference/74181782 101. Wesierska-Gadek 2006: Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis., Hepatology, 43, p. 1135, DOI: 10.1002/hep.21172 101 10.1002/hep.21172 false true Reference 74181783 /api/reference/74181783 102. Gatselis 2020: Factors associated with progression and outcomes of early stage primary biliary cholangitis., Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., 18, p. 684 102 false true Reference 74181784 /api/reference/74181784 103. Bian 2021: The clinical and laboratory features associated with cancer in patients with primary biliary cholangitis: a longitudinal survey-based study., Clin. Rheumatol., 40, p. 3311, DOI: 10.1007/s10067-021-05657-z 103 10.1007/s10067-021-05657-z false true Reference 74181785 /api/reference/74181785 104. Liang 2012: Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis., Hepatology, 56, p. 1409, DOI: 10.1002/hep.25788 104 10.1002/hep.25788 false true Reference 74181786 /api/reference/74181786 105. Tanaka 2020: Recurrence of disease following organ transplantation in autoimmune liver disease and systemic lupus erythematosus., Cell. Immunol., 347, DOI: 10.1016/j.cellimm.2019.104021 105 10.1016/j.cellimm.2019.104021 false true Reference 74181787 /api/reference/74181787 106. De Liso 2017: The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: a review of literature., Clin. Chem. Lab. Med. CCLM, 56, p. 25, DOI: 10.1515/cclm-2017-0249 106 10.1515/cclm-2017-0249 false true Reference 74181788 /api/reference/74181788 107. John 2022: Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis., Liver Int. Off. J. Int. Assoc. Study Liver, 42, p. 384 107 false true Reference 74181789 /api/reference/74181789 108. Liu 2008: Antimitochondrial antibody‐negative primary biliary cirrhosis: a subset of primary biliary cirrhosis., Liver Int., 28, p. 233, DOI: 10.1111/j.1478-3231.2007.01651.x 108 10.1111/j.1478-3231.2007.01651.x false true Reference 74181790 /api/reference/74181790 109. Cançado 2022: Members of the Brazilian cholestasis study group consortium, anti-mitochondrial antibody-negative primary biliary cholangitis is part of the same spectrum of classical primary biliary cholangitis., Dig. Dis. Sci., 67, p. 3305, DOI: 10.1007/s10620-021-07122-y 109 10.1007/s10620-021-07122-y false true Reference 74181791 /api/reference/74181791 110. Liu 2025: Comparison of pathological features of patients with antibody-negative and positive primary biliary cholangitis., BMC Gastroenterol., 25, p. 667, DOI: 10.1186/s12876-025-04280-5 110 10.1186/s12876-025-04280-5 false true Reference 74181792 /api/reference/74181792 111. Michieletti 1994: Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis., Gut, 35, p. 260, DOI: 10.1136/gut.35.2.260 111 10.1136/gut.35.2.260 false true Reference 74181793 /api/reference/74181793 112. Nakajima 1999: Detection of IgA, IgM, and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary biliary cirrhosis?., J. Gastroenterol., 34, p. 607, DOI: 10.1007/s005350050380 112 10.1007/s005350050380 false true Reference 74181794 /api/reference/74181794 113. Juliusson 2016: Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis., Scand. J. Gastroenterol., 51, p. 745, DOI: 10.3109/00365521.2015.1132337 113 10.3109/00365521.2015.1132337 false true Reference 74181795 /api/reference/74181795 114. Jin 2012: Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis., Hepatol. Baltim. Md, 55, p. 1495, DOI: 10.1002/hep.25511 114 10.1002/hep.25511 false true Reference 74181796 /api/reference/74181796 115. Dahlqvist 2017: Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis., Hepatol. Baltim. Md, 65, p. 152, DOI: 10.1002/hep.28859 115 10.1002/hep.28859 false true Reference 74181797 /api/reference/74181797 116. Zandanell 2020: Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody-positive subjects over six years of follow-up., J. Intern. Med., 287, p. 395, DOI: 10.1111/joim.13005 116 10.1111/joim.13005 false true Reference 74181798 /api/reference/74181798 117. Ergenc 2023: The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients., Hepatol. Forum, 4, p. 69 117 false true Reference 74181799 /api/reference/74181799 118. Li 2025: Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive., Clin. Mol. Hepatol., 31, p. 474, DOI: 10.3350/cmh.2024.0416 118 10.3350/cmh.2024.0416 false true Reference 74181800 /api/reference/74181800 119. Mitchison 1986: Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?., Hepatol. Baltim. Md, 6, p. 1279, DOI: 10.1002/hep.1840060609 119 10.1002/hep.1840060609 false true Reference 74181801 /api/reference/74181801 120. Sun 2019: Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: is alkaline phosphatase truly a surrogate marker?., J. Autoimmun., 99, p. 33, DOI: 10.1016/j.jaut.2019.01.005 120 10.1016/j.jaut.2019.01.005 false true Reference 74181802 /api/reference/74181802 121. Berdichevski 2017: Positive antimitochondrial antibody but normal serum alkaline phosphatase levels: could it be primary biliary cholangitis?., Hepatol. Res. Off. J. Jpn. Soc. Hepatol., 47, p. 742, DOI: 10.1111/hepr.12809 121 10.1111/hepr.12809 false true Reference 74181803 /api/reference/74181803 122. Corpechot 2010: Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis., J. Hepatol., 53, p. 162, DOI: 10.1016/j.jhep.2010.02.019 122 10.1016/j.jhep.2010.02.019 false true Reference 74181804 /api/reference/74181804 123. Gershwin 2005: Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients., Hepatol. Baltim. Md, 42, p. 1194, DOI: 10.1002/hep.20907 123 10.1002/hep.20907 false true Reference 74181805 /api/reference/74181805 124. Thomsen 2020: Familial associations between autoimmune hepatitis and primary biliary cholangitis and other autoimmune diseases., PLoS One, 15, DOI: 10.1371/journal.pone.0240794 124 10.1371/journal.pone.0240794 false true Reference 74181806 /api/reference/74181806 125. Örnolfsson 2018: Using the Icelandic genealogical database to define the familial risk of primary biliary cholangitis., Hepatol. Baltim. Md, 68, p. 166, DOI: 10.1002/hep.29675 125 10.1002/hep.29675 false true Reference 74181807 /api/reference/74181807 126. Lazaridis 2007: Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis., Hepatology, 46, p. 785, DOI: 10.1002/hep.21749 126 10.1002/hep.21749 false true Reference 74181808 /api/reference/74181808 127. Zografos 2012: Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients., World J. Gastroenterol., 18, p. 4721, DOI: 10.3748/wjg.v18.i34.4721 127 10.3748/wjg.v18.i34.4721 false true Reference 74181809 /api/reference/74181809 128. Gulamhusein 2016: Low incidence of primary biliary cirrhosis (PBC) in the first-degree relatives of PBC probands after 8 years of follow-up., Liver Int. Off. J. Int. Assoc. Study Liver, 36, p. 1378 128 false true Reference 74181810 /api/reference/74181810 129. Selmi 2004: Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment., Gastroenterology, 127, p. 485, DOI: 10.1053/j.gastro.2004.05.005 129 10.1053/j.gastro.2004.05.005 false true Reference 74181811 /api/reference/74181811 130. Mells 2014: Primary biliary cirrhosis: family, genes, and bugs., Clin. Liver Dis., 3, p. 69, DOI: 10.1002/cld.308 130 10.1002/cld.308 false true Reference 74181812 /api/reference/74181812 131. Smyk 2011: Primary biliary cirrhosis: family stories., Autoimmune Dis., 2011 131 false true Reference 74181813 /api/reference/74181813 132. Dalekos 2019: Variant and specific forms of autoimmune cholestatic liver diseases., Arch. Immunol. Ther. Exp., 67, p. 197, DOI: 10.1007/s00005-019-00550-9 132 10.1007/s00005-019-00550-9 false true Reference 74181814 /api/reference/74181814 133. Liu 2010: PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis., J. Autoimmun., 35, p. 436, DOI: 10.1016/j.jaut.2010.09.005 133 10.1016/j.jaut.2010.09.005 false true Reference 74181815 /api/reference/74181815 134. Muratori 2005: The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis., Dig. Liver Dis., 37, p. 108, DOI: 10.1016/j.dld.2004.09.019 134 10.1016/j.dld.2004.09.019 false true Reference 74181816 /api/reference/74181816 135. Jacobs 2018: Standardization and harmonization of autoimmune diagnostics., Clin. Chem. Lab. Med. CCLM, 56, p. 1563, DOI: 10.1515/cclm-2018-0807 135 10.1515/cclm-2018-0807 false true Reference 74181817 /api/reference/74181817 136. Oyaert 2026: Towards harmonization of autoantibody detection in relation to paraneoplastic neurological syndromes (PNS): a European survey on laboratory practices., Clin. Chem. Lab. Med. CCLM, 64, p. 390, DOI: 10.1515/cclm-2025-1030 136 10.1515/cclm-2025-1030 false true Reference 74181818 /api/reference/74181818 137. Monogioudi 2018: Standardization of autoimmune testing – is it feasible?., Clin. Chem. Lab. Med. CCLM, 56, p. 1734, DOI: 10.1515/cclm-2017-1077 137 10.1515/cclm-2017-1077 false true Reference 74181819 /api/reference/74181819 138. Tozzoli 2017: Challenges in the standardization of autoantibody testing: a comprehensive review., Clin. Rev. Allergy Immunol., 53, p. 68, DOI: 10.1007/s12016-016-8579-y 138 10.1007/s12016-016-8579-y false true Reference 74181820 /api/reference/74181820 139. Bossuyt 2020: Standardisation of PR3-ANCA and MPO-ANCA: evaluation of certified reference materials., Ann. Rheum. Dis., 79, p. 1520, DOI: 10.1136/annrheumdis-2020-217416 139 10.1136/annrheumdis-2020-217416 false true Reference 74181821 /api/reference/74181821 140. Grossi 2025: Antiphospholipid IgG certified reference material ERM® -DA477/IFCC: a tool for aPL harmonization?., Clin. Chem. Lab. Med. CCLM, 63, p. 1315, DOI: 10.1515/cclm-2025-0032 140 10.1515/cclm-2025-0032 false true Reference 74181822 /api/reference/74181822 141. Zhang 2025: Development of a chimeric monoclonal antibody as a potential diagnostic reference in PR3-ANCA detection., J. Immunol. Methods, 542, DOI: 10.1016/j.jim.2025.113903 141 10.1016/j.jim.2025.113903 false true Reference 74181823 /api/reference/74181823 142. Damoiseaux 2020: The perspective on standardisation and harmonisation: the viewpoint of the EASI president., Autoimmun. Highlights, 11, p. 4, DOI: 10.1186/s13317-020-0127-3 142 10.1186/s13317-020-0127-3 false true Reference 74181824 /api/reference/74181824 143. Andrade 2024: Reflecting on a decade of the international consensus on ANA patterns (ICAP): accomplishments and challenges from the perspective of the 7th ICAP workshop., Autoimmun. Rev., 23, DOI: 10.1016/j.autrev.2024.103608 143 10.1016/j.autrev.2024.103608 false true Reference 74181825 /api/reference/74181825 144. Bonroy 2023: Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP., Clin. Chem. Lab. Med. CCLM, 61, p. 1167, DOI: 10.1515/cclm-2023-0209 144 10.1515/cclm-2023-0209 false true Reference 74181826 /api/reference/74181826 145. Bossuyt 2024: Reporting likelihood ratio in autoimmune serology: just a theory or feasible in practice?., Clin. Chem., 70, p. 482, DOI: 10.1093/clinchem/hvad222 145 10.1093/clinchem/hvad222 false true Reference 74181827 /api/reference/74181827 146. Zhang 2019: Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis., Gastroenterol. Res. Pract., 2019, p. 1 146 false true Reference 74181828 /api/reference/74181828 147. Colapietro 2023: PPAR agonists for the treatment of primary biliary cholangitis: old and new tales., J. Transl. Autoimmun., 6, DOI: 10.1016/j.jtauto.2023.100188 147 10.1016/j.jtauto.2023.100188 false true Reference 74181829 /api/reference/74181829 148. Mimura 2025: Autoantibodies in primary biliary cholangitis: from classical markers to emerging targets., J. Clin. Med., 14, p. 8503, DOI: 10.3390/jcm14238503 148 10.3390/jcm14238503 false true Reference 74181830 /api/reference/74181830 149. Janmohamed 2018: Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)., Best Pract. Res. Clin. Gastroenterol., 34–35, p. 71, DOI: 10.1016/j.bpg.2018.06.002 149 10.1016/j.bpg.2018.06.002 false true Reference 74181831 /api/reference/74181831 150. Bizzaro 2014: Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems., Autoimmun. Rev., 13, p. 292, DOI: 10.1016/j.autrev.2013.10.015 150 10.1016/j.autrev.2013.10.015 false true Reference 74181832 /api/reference/74181832 151. Tozzoli 2012: Automation in indirect immunofluorescence testing: a new step in the evolution of the autoimmunology laboratory., Autoimmun. Highlights, 3, p. 59, DOI: 10.1007/s13317-012-0035-2 151 10.1007/s13317-012-0035-2 false true Reference 74181833 /api/reference/74181833 152. Nagy 2020: Anti-neutrophil cytoplasmic antibody testing by indirect immunofluorescence: computer-aided versus conventional microscopic evaluation of routine diagnostic samples from patients with vasculitis or other inflammatory diseases., Clin. Chim. Acta, 511, p. 117, DOI: 10.1016/j.cca.2020.09.031 152 10.1016/j.cca.2020.09.031 false true Reference 74181834 /api/reference/74181834 153. Damoiseaux 2016: Multiparametric autoimmune diagnostics: recent advances., Pathol. Lab. Med. Int., 15 153 false true Reference 74181835 /api/reference/74181835 154. Vanderlocht 2017: Multiplex autoantibody detection for autoimmune liver diseases and autoimmune gastritis., J. Immunol. Methods, 448, p. 21, DOI: 10.1016/j.jim.2017.05.003 154 10.1016/j.jim.2017.05.003 false true Reference 74181836 /api/reference/74181836 155. Villalta 2020: Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis., Clin. Chem. Lab. Med. CCLM, 58, p. 1499, DOI: 10.1515/cclm-2020-0122 155 10.1515/cclm-2020-0122 false true Reference 74181837 /api/reference/74181837 156. Oertelt 2007: A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis., Hepatology, 45, p. 659, DOI: 10.1002/hep.21583 156 10.1002/hep.21583 false true Reference 74181838 /api/reference/74181838 157. Zhao 2022: Using two-step cluster analysis to classify inpatients with primary biliary cholangitis based on autoantibodies: a real-world retrospective study of 537 patients in China., Front. Immunol., 13 157 false true /api/publication/37057169 Antal-Szalmás Péter et al. Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis. (2026) JOURNAL OF TRANSLATIONAL AUTOIMMUNITY 2589-9090 12<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10009455"><a href="/gui2/?type=authors&mode=browse&sel=10009455" target="_blank">Antal-Szalmás Péter (<span class="authorship-author-name">Antal-Szalmás Péter</span> <span class="authorAux-mtmt"> Immunológia</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Laboratóriumi Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10068399"><a href="/gui2/?type=authors&mode=browse&sel=10068399" target="_blank">Bencze Dóra (<span class="authorship-author-name">Bencze Dóra</span> <span class="authorAux-mtmt"> immunológia, laboratóriumi medicina</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Immunológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Demeter Sarolta </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10036832"><a href="/gui2/?type=authors&mode=browse&sel=10036832" target="_blank">Pénzes-Daku Krisztina (<span class="authorship-author-name">Pénzes-Daku Krisztina</span> <span class="authorAux-mtmt"> trombózis-hemosztázis</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/<span title="Laboratóriumi Medicina Intézet">LMI</span>/Klinikai Laboratóriumi Kutató Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Szabó Lilla </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10036104"><a href="/gui2/?type=authors&mode=browse&sel=10036104" target="_blank">Tóth Beáta (<span class="authorship-author-name">Tóth Beáta</span> <span class="authorAux-mtmt"> molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Laboratóriumi Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Földesi Róza </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10015739"><a href="/gui2/?type=authors&mode=browse&sel=10015739" target="_blank">Papp Mária (<span class="authorship-author-name">Papp Mária</span> <span class="authorAux-mtmt"> Belgyógyászat, gasztroenterológia</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/<span title="Belgyógyászati Intézet">BelgyI</span>/Gasztroenterológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10078258"><a href="/gui2/?type=authors&mode=browse&sel=10078258" target="_blank">Nagy Gábor (<span class="authorship-author-name">Nagy Gábor</span> <span class="authorAux-mtmt"> laboratóriumi diagnosztika</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Laboratóriumi Medicina Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;37057169" target="_blank">Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis</a></div> <div> <span class="journal-title">JOURNAL OF TRANSLATIONAL AUTOIMMUNITY</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2589-9090">2589-9090</a>)</span>: <span class="journal-volume">12</span> <span class="page"> Paper 100366. </span> <span class="year">(2026)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1016/j.jtauto.2026.100366" target="_blank" href="https://doi.org/10.1016/j.jtauto.2026.100366"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001734367500001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001734367500001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105034685687" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105034685687"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:black" title="https://linkinghub.elsevier.com/retrieve/pii/S2589909026000195" target="_blank" href="https://linkinghub.elsevier.com/retrieve/pii/S2589909026000195"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Immunology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Immunology and Allergy&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 2</span> | Független: 2 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 2 | Scopus jelölt:&nbsp;2 | WoS/Scopus jelölt:&nbsp;2 | DOI jelölt:&nbsp;2 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;37057169&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 2 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 37057169</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">WoS-XML</span> </div> <div class="lastModified">Utolsó módosítás: 2026.05.20. 10:50 Szuper Admin (admin) </div> </div></div>